Carcinoembryonic antigen (CEA), an oncofetal cell surface glycoprotein, has been widely used as a human tumor marker due to its high expression in tumors and secretion to serum. It belongs to the immunoglobulin superfamily named CEA-related cell adhesion molecule (CEACAM) family. Members of this family are detected in various cancers and have been shown to be involved in cancer growth and invasion. In this study, we examined the mRNA expression profiles of CEACAM family members including CEACAM1, CEACAM3, CEACAM4, CEACAM5 (CEA), CEACAM6, CEACAM7, and CEACAM8 in various tumor cell lines. Our screening data indicated that the mRNA expression patterns of CEACAMs in TT cells, which are derived from medullary thyroid carcinoma (MTC), were distinct from other tumor cell lines. Additionally, CEACAM4 was only expressed in TT cells, in which two novel splice variants of CEACAM4 were expressed. These findings suggested that production of CEA and CEA-related molecules in MTC may be distinct from other tumor-based production of those molecules and that the specific expression of CEACAM4 would make possible to differentiate between MTC and other CEA-producing tumors.
Carcinoembryonic antigen (CEA) is the product of the CEA-related cell adhesion molecule 5 (CEACAM5) gene and is produced in a high percentage of human tumors, including 90% of gastrointestinal cancers, 70% of lung cancers, and 50% of breast cancers (22) . Because of its high secretion into the serum, CEA has been widely used as a serum tumor marker; currently, CEA analysis is used to monitor the progression of several types of cancer following surgery. CEA belongs to the CEACAM subfamily of the immunoglobulin (Ig) superfamily. The members of this family have been identified as CEA crossreacting antigens and have been found in tumor sites with elevated CEA-like activity. Moreover, CEACAMs are also produced in various tumors, and recent studies have suggested that multivariable analysis of CEACAMs may improve the clinical utility of CEA as a tumor maker (6, 24) . For example, Simeone et al. reported that CEACAM1 may be used to enhance the efficacy of other known pancreatic tumor markers and may have better sensitivity and specificity than CA19-9 and CEA for the detection of pancreatic carcinoma (20) . In addition, using those biomarkers in combination with CEACAM1 may represent a novel method for the diagnosis of early-stage pancreatic carcinoma.
In this study, we analyzed the mRNA expression profiles of CEACAM family members in colonic, gastric, pancreatic, lung, breast, and thyroid cancer cell lines. Our data demonstrated that a medullary thyroid carcinoma (MTC)-derived cell line exhibited unique CEACAM expression patterns, with CEACAM4 specifically expressed in TT cells.
PCR products visualized under ultraviolet light were isolated from agarose gels and purified using a QIAquick Gel Extraction Kit (Qiagen). The purified samples were then cloned into a pCR 2.1-TOPO vector (Invitrogen) using a TOPO TA Cloning Kit for Sequencing (Invitrogen). Positive transformants were sequenced using a Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3130xl Genetic Analyzer (Applied Biosystems). The protein-coding sequences obtained by the DNA sequencing were deposited in the DNA Data Bank of Japan (DDBJ; accession numbers AB924369 and AB924370).
RESULTS AND DISCUSSION
To investigate the mRNA expression profiles of CEACAM transcripts in various cancer cell lines, RT-PCR screening was carried out using the specific primer sets listed in Table 1 . CEACAM1, CEACAM5 (CEA), and CEACAM6 have been shown to be expressed in various cancer cells (2) . Consistent with this, our data demonstrated that CEACAM1, CEACAM5, and CEACAM6 were expressed in the majority of colonic, gastric, pancreatic, breast, and lung cancer cell lines ( Table 2 ). CEACAM3 and CEACAM7 exhibited more restricted expression, but did not show tumor type-specific expression. On the other hand, CEACAM8 was specifically expressed in colonic cancer cell lines. CEACAM8 has been shown to be expressed mainly in granulocytes and is thought to play an important role in intracellular signaling events (5, 7, 23) . However, the tumorassociated features of CEACAM8 remain unknown. Our screening data suggested that CEACAM8 may be expressed in tumor cells and may interact with closely related CEACAMs, as has been observed in granulocytes. Interestingly, one of the thyroid carcinoma cell lines, TT, expressed most of the CEACAMs except for CEACAM8; this expression profile was distinct from other cell lines. Moreover, CEACAM4
MATERIALS AND METHODS
Cell culture. Cancer cell lines were purchased from the American Type Culture Collection (ATCC), Dainippon Sumitomo Pharma (DSP, Osaka, Japan), Immuno-Biological Laboratories (IBL, Gunma, Japan), and the Japanese Collection of Research Bioresources (JCRB). All cell lines were maintained in RPMI 1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA), glutamine (0.3 mg/mL), penicillin (100 U/mL), and streptomycin (0.1 mg/ mL) in a humidified 5% CO 2 incubator.
RNA extraction and cDNA synthesis. Total RNA was extracted from cells using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and purified using an RNeasy MinElute Cleanup Kit (Qiagen) according to the manufacturer's instructions. The concentration was determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). First strand cDNAs were prepared from the purified total RNA and total RNA derived from normal thyroid tissues (Clontech, Mountain View, CA) in a reverse transcription reaction using PrimeScript II RTase (Takara Bio, Shiga, Japan) and oligo(dT) 20 primers according to the manufacturer's instructions.
Reverse transcription polymerase chain reaction (RT-PCR).
Screening for the expression of CEACAM transcripts was carried out by PCR in a TGradient Thermocycler (Biometra GmbH, Göttingen, Germany) with LA Taq polymerase (Takara) and specific primer sets ( Table 1 ). The PCR analysis consisted of hot-start incubation at 95°C for 2 min and 35 cycles of 95°C for 30 s, 60°C for 30 s, and 68°C for 15 s. The resulting amplicons were separated by 1-2% agarose gel electrophoresis and detected with SYBR Safe (Invitrogen, Carlsbad, CA, USA).
DNA sequencing. For DNA sequencing analysis, MTC-specific CEACAM family member.
To gain more insight into the expression of CEACAM4 mRNA in TT cells, we analyzed the sequences of CEACAM4 transcripts. As shown in was only expressed in TT cells though other thyroid carcinoma cell lines did not express CEACAM4. TT is the only cell line that is thyroid C cell-derived carcinoma MTC, suggesting that CEACAM4 is an Table 2 mRNA expression profiles of CEACAM family members in cancer cell lines associated with band-b was identified as CEACAM4 and registered in GenBank (NM_001817.3). The novel splice form of CEACAM4-sv1, detected in region "a", had an insertion of an intronic region between exons 6 and 7. The exon structure of band-c, assumed to be a novel splice form of CEACAM4-sv2, skipped exon 3. These alternative splicing events cause frame shift mutations, causing the predicted amino acid sequences derived from the novel splice variants to be distinct from those of the known CEACAM4 protein (Fig. 2) . These results revealed that TT cells expressed three forms of CEACAM4 transcripts, including two novel splice variants.
MTC is a rare malignancy that accounts for 5-10% of all thyroid carcinomas and is often associated with mutations in the RET proto-oncogene (9, (15) (16) (17) . CEA is also a sensitive tumor marker for MTC (14) . Analysis of the serum levels of CEA and calcitonin are important for surveillance of patients with MTC, but have not been shown to be related to progressive or stable status of the disease (13, 14) . Tumor-related CEACAMs, including CEA, have been shown to be expressed in a variety of epithelium-derived neoplasms, such as colonic, gastric, breast, and lung carcinomas (18, 19, 21) . However, among CEA-producing tumors, MTC is a unique tumor that arises from well-differentiated thyroid Ccells, which represent less than 1% of all thyroid cells. Moreover, CEACAM expression exhibits considerable heterogeneity within tumors, which may be attributable to the variations in tumor-derived organs. Based on these findings, we would expect that Fig. 1A , three transcript lengths (band-a, -b, and -c) were detected in TT cells. From DNA sequencing results, we identified two novel splice variants, termed CEACAM4-sv1 and -sv2 (Fig. 1B) . The transcript the production of CEA may be different between MTC and other tumor types. Additionally, CEA and other CEACAMs were previously reported to be the MTC-related gene. CEACAM6 and CEACAM7 are upregulated in patients with MEN2B-MTC, which has similar gene expression profiles to the human MTC cell line TT, bearing the RET 634 mutation (1, 3, 4, 10) . In support of this, our screening data indicated that TT cells expressed several CEACAMs, including CEACAM6, CEACAM7, and an MTCspecific CEACAM member CEACAM4 (Table 2) . Meanwhile, normal thyroid tissues did not express those MTC-related CEACAM family members (data not shown). These data suggested that analysis of CEACAM expression may allow for the differentiation between MTC and other CEA-producing tumors. CEACAM4, also called CEA gene family member 7 (CGM7), was originally identified from human peripheral leukocytes as a nonspecific cross-reacting antigen (NCA)-related molecule in human granulocytes (12) . Although the molecular structure of CEACAM4 is similar to that of CEACAM3, which is expressed in granulocytes, CEACAM4 exhibits low similarities to the other CEACAM family members. However, little is known about the tissue distribution of CEACAM4 (8, 11) . This is the first report to demonstrate that CEACAM4 is expressed in tumor-derived cell lines and this expression is specific to an MTC-derived cell line. Moreover, we identified two novel splice variants of CEACAM4, which may provide insights into the molecular characteristics of specific tumor types. Further studies are currently being performed in our laboratory to verify the specificity of CEACAM4 expression and its function in MTC.
